{"title":"Galderma","description":"Everyone's skin is unique and we each have our own skin story. At Galderma, we embrace these differences and offer cutting-edge, premium brands that fit people's individual needs, across the full spectrum of dermatology through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.","products":[{"product_id":"restylane-refyne-lido-1x1ml","title":"Restylane Refyne Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eRestylane Refyne is a dermal filler designed to smooth and soften lines and wrinkles, such as moderate smile lines and lines around the mouth. Designed with XpresHAn Technology™ for flexible refinement of dynamic areas, Restylane Refyne moves with your expressions for natural-looking results.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558077196,"sku":"GALRESREF2","price":90.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALRESREF2.jpg?v=1774870246"},{"product_id":"restylane-defyne-lido-1x1ml","title":"Restylane Defyne Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eRestylane Defyne is a hyaluronic acid (HA) filler that helps to soften deep laugh lines, such as nasolabial folds, and can be used to define the shape of the chin. Restylane Defyne can correct mild-to-moderate chin retrusion, with 98% of patients having improved double chin appearance after treatment.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558109964,"sku":"GALRESDEF2","price":89.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/EME001QME02.jpg?v=1712590116"},{"product_id":"restylane-kysse-lido-1x1ml","title":"Restylane Kysse Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eRestylane Kysse was designed specifically with movement in mind. It’s made with XpresHAn Technology™, an innovative crosslinked hyaluronic acid (HA) gel created for precise, natural-looking results. With the ideal balance of flexibility, support, and a natural feel, you can maintain a full range of expressions.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558142732,"sku":"GALRESKYS2","price":102.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/EME003QME01.jpg?v=1712590124"},{"product_id":"restylane-volyme-lido-1x1ml","title":"Restylane Volyme Lido (1x1ml)","description":null,"brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558306572,"sku":"GALRESVOL2","price":90.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/EME004QME01.jpg?v=1712590187"},{"product_id":"restylane-classic-lido-1x1ml","title":"Restylane Classic Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eThe original hyaluronic acid gel dermal filler. Specifically formulated to act like your body's own naturally produced hyaluronic acid, Restylane provides support and structure in the lips and smile lines.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558372108,"sku":"GALRESLID1","price":84.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALRESLID1.jpg?v=1774870245"},{"product_id":"restylane-lyft-lido-1x1ml","title":"Restylane Lyft Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eRestylane Lyft is a safe, effective, and dissolvable HA filler specifically designed to create structure in the cheek area or add fullness in the backs of the hands by replenishing lost volume for a more youthful-looking appearance.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558404876,"sku":"GALRESLIDLYF2","price":92.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALRESLIDLYF2.jpg?v=1774870245"},{"product_id":"restylane-skinbooster-vital-lido-1x1ml","title":"Restylane Skinbooster Vital Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eRestylane Vital is a treatment that enhances skin quality and hydration by replenishing hyaluronic acid, formulated for mature or sun-damaged skin, offering more intense hydration and addressing firmness and elasticity.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558503180,"sku":"GALSKNBOO2","price":42.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALSKNBOO2_e65e82f1-4745-4351-a450-a841b5707b2f.jpg?v=1774870321"},{"product_id":"sculptra-2-vials","title":"Sculptra x 2 vials 300mg","description":"\u003cp\u003e\u003cspan\u003eSculptra is a regenerative biostimulator used to restore facial volume and reduce wrinkles by stimulating collagen production. It's a poly-L-lactic acid (PLLA) based filler that works by stimulating the body's natural collagen production, leading to gradual and natural-looking results. Sculptra is considered a long-lasting treatment, with results potentially lasting up to two years. \u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558535948,"sku":"GALSCU002SAN01","price":323.99,"currency_code":"EUR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/SCU002SAN01.jpg?v=1712753715"},{"product_id":"restylane-skinbooster-vital-light-lido-1x1ml","title":"Restylane Skinbooster Vital LIGHT Lido (1x1ml)","description":"\u003cp\u003e\u003cspan\u003eRestylane Vital Light is a lighter formulation, ideal for younger or delicate skin, or areas where a more subtle approach is preferred, such as the neck and décolletage. \u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":45374558568716,"sku":"GALSKNBOOLIG2","price":42.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/RESVL1QME01.jpg?v=1712669975"},{"product_id":"azzalure-twin-pack-roi-125-speywood-ml","title":"Azzalure Twin Pack ROI 125 Speywood\/ml (POM)","description":"\u003cp\u003e\u003cspan\u003e*THIS IS A COLD CHAIN PRODUCT, PLEASE STORE BETWEEN 2°C to 8°C UPON RECEIPT*\u003cbr\u003e\u003cbr\u003eAzzalure is indicated for the temporary improvement in the appearance of moderate to severe Glabellar lines (vertical lines between the eyebrows) seen at maximum frown and\/or Lateral canthal lines (crow's feet lines) seen at maximum smile in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":54386284101900,"sku":"GALAZZ250TWIN","price":149.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALAZZ250TWIN.jpg?v=1751465322"},{"product_id":"alluzience-twin-pack-roi-200-speywood-ml","title":"Alluzience Twin Pack ROI 200 Speywood\/ml (POM)","description":"\u003cp\u003e\u003cspan\u003eAlluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) seen at maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":54416349266188,"sku":"GALALLUZ250TWIN","price":158.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALALLUZ250TWIN.jpg?v=1753799901"},{"product_id":"restylane-eyelight-0-5ml","title":"Restylane Eyelight 0.5ml","description":"\u003cp\u003e\u003cspan\u003eRestylane Eyelight is an FDA-approved hyaluronic acid (HA) dermal filler formulated with NASHA® Technology, which has a firm gel texture resulting in targeted product placement, helping it stay in place. Restylane Eyelight fills in the undereye area to reduce shadows.\u003c\/span\u003e\u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":54426434175244,"sku":"GALRESEYE51","price":76.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALRESEYE5.jpg?v=1754580649"},{"product_id":"relfydess-100-units","title":"Relfydess™▼ (relabotulinumtoxinA) 100 units\/ml 1.5ml Single Vial (POM) (cold chain)","description":"\u003cp class=\"MsoNormal\" align=\"center\" style=\"text-align: center;\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 12.0pt; line-height: 115%;\"\u003eThis content has been developed by Galderma and is intended for Healthcare Professionals Only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" align=\"center\" style=\"text-align: center;\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 12.0pt; line-height: 115%;\"\u003eIE-REL-2600026 Date of Production March 2026\u003c\/span\u003e\u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp class=\"MsoNormal\" align=\"center\" style=\"text-align: center;\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 12.0pt; line-height: 115%;\"\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; color: black; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;\"\u003eprescribing information and adverse event reporting can be found at the bottom of the page \u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003cp class=\"MsoNormal\"\u003e \u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp\u003eRelfydess™▼ is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines at maximum frown and moderate-to-severe lateral canthal lines at maximum smile alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. \u003cspan style=\"font-size: 12.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; color: black; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;\"\u003eRelfydess SmPC\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003cp class=\"MsoNormal\"\u003e \u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan\u003eRelfydess™ ▼ (RelabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology, developed and manufactured by Galderma. \u003cspan style=\"font-size: 12.0pt; font-family: 'Aptos',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; color: black; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;\"\u003eRelfydess SmPC\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003cp class=\"MsoNormal\"\u003e \u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 11.0pt; line-height: 115%;\"\u003eRelfydess™▼ 100 units\/mL solution for injection - Prescribing Information:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"margin-right: -52.5pt;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Times New Roman',serif;\"\u003eRelfydess▼\u003c\/span\u003e\u003c\/b\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003cspan style=\"mso-spacerun: yes;\"\u003e \u003c\/span\u003e100 units\/mL solution for injection - Prescribing Information (Ireland) – alternative version\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"margin-right: -52.5pt;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"mso-outline-level: 1;\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e‘Undesirable Effects’\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003efor how to report adverse reactions.\u003c\/span\u003e\u003cspan style=\"mso-bidi-font-size: 11.0pt;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"margin-right: -52.5pt;\"\u003e \u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"margin-right: -52.5pt;\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003ePresentation: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003eE\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003each vial contains 150 units of b\u003cspan style=\"mso-bidi-font-weight: bold;\"\u003eotulinum toxin type A 100 units\/mL manufactured from \u003ci\u003eClostridium botulinum \u003c\/i\u003ein 1.5 mL of solution.\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"text-indent: 42.55pt; margin: 0cm -52.5pt .0001pt -42.55pt;\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eIndications: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eRelfydess is indicated for the temporary improvement in the appearance of: \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"text-indent: -18.0pt; mso-list: l1 level1 lfo1; margin: 0cm -52.5pt .0001pt 36.0pt;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003eModerate to severe glabellar lines at maximum frown\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"text-indent: -18.0pt; mso-list: l1 level1 lfo1; margin: 0cm -52.5pt .0001pt 36.0pt;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003eModerate to severe lateral canthal lines seen at maximum smile \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\" style=\"margin-right: -52.5pt;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003ealone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: Calibri; mso-font-kerning: 0pt; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eDosage:\u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003e \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eThe treatment interval should be no more frequently than every twelve weeks. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-ansi-language: EN-US;\"\u003eThe efficacy and safety of the repeated administration of this product has not been studied for more than 52 weeks. \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eConsideration of the cumulative dose is necessary if other botulinum toxin products are being or have been used to treat other indications for those products. The potency units are specific to Relfydess and are not interchangeable with other preparations of botulinum toxin. Relfydess is ready-to-use with a concentration of 10 units per 0.1 mL and no reconstitution is required.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-font-kerning: 0pt; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"\u003eDosing Instructions for Relfydess\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cdiv align=\"center\"\u003e\n\u003ctable class=\"MsoNormalTable\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\" style=\"width: 100.0%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm .5pt 0cm .5pt;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"mso-yfti-irow: 0; mso-yfti-firstrow: yes; page-break-inside: avoid;\"\u003e\n\u003ctd width=\"168\" valign=\"top\" style=\"width: 125.65pt; border: solid black 1.0pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e\u003cb\u003e\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003eTreatment(s)\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"169\" valign=\"top\" style=\"width: 126.55pt; border: solid black 1.0pt; border-left: none; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e\u003cb\u003e\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003eTotal Recommended Dose\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"265\" valign=\"top\" style=\"width: 198.6pt; border: solid black 1.0pt; border-left: none; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e\u003cb\u003e\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003eDose per injection\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"mso-yfti-irow: 1; page-break-inside: avoid;\"\u003e\n\u003ctd width=\"168\" style=\"width: 125.65pt; border: solid black 1.0pt; border-top: none; mso-border-top-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003eGlabellar Lines (GL)\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"169\" style=\"width: 126.55pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid black 1.0pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e50 units (0.5 mL) \u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"265\" style=\"width: 198.6pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid black 1.0pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e5 injections of 10 units (0.1 mL):\u003c\/p\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e2 injections on each side at the \u003ci style=\"mso-bidi-font-style: normal;\"\u003ecorrugator\u003c\/i\u003e muscle and 1 injection at the \u003ci style=\"mso-bidi-font-style: normal;\"\u003eprocerus\u003c\/i\u003e muscle near the nasofrontal angle\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"mso-yfti-irow: 2; page-break-inside: avoid;\"\u003e\n\u003ctd width=\"168\" style=\"width: 125.65pt; border: solid black 1.0pt; border-top: none; mso-border-top-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003eLateral Canthal Lines (LCL)\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"169\" style=\"width: 126.55pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid black 1.0pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e60 units (0.6 mL)\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"265\" style=\"width: 198.6pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid black 1.0pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e6 injections of 10 units (0.1 mL):\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"page-break-after: avoid;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e3 injections on each side at the \u003ci style=\"mso-bidi-font-style: normal;\"\u003eorbicularis oculi\u003c\/i\u003e muscle \u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"mso-yfti-irow: 3; mso-yfti-lastrow: yes; page-break-inside: avoid;\"\u003e\n\u003ctd width=\"168\" style=\"width: 125.65pt; border: solid black 1.0pt; border-top: none; mso-border-top-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003eCombined treatment of Glabellar Lines and Lateral Canthal Lines\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"169\" style=\"width: 126.55pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid black 1.0pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e110 units (1.1 mL) \u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd width=\"265\" style=\"width: 198.6pt; border-top: none; border-left: none; border-bottom: solid black 1.0pt; border-right: solid black 1.0pt; mso-border-top-alt: solid black .5pt; mso-border-left-alt: solid black .5pt; mso-border-alt: solid black .5pt; padding: 0cm 5.4pt 0cm 5.4pt;\"\u003e\n\u003cp class=\"MsoCommentText\" style=\"page-break-after: avoid;\"\u003e11 injections total of 10 units (0.1 mL) for combined GL and LCL\u003cspan lang=\"EN-US\" style=\"mso-ansi-language: EN-US;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eGeneral information\u003c\/span\u003e\u003c\/i\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eIn the event of treatment failure or diminished effect following repeat injections, alternative treatment methods should be employed. In case of treatment failure after the first treatment session, the following approaches may be considered:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l2 level1 lfo2; mso-hyphenate: auto; tab-stops: 35.45pt; text-autospace: ideograph-numeric ideograph-other;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eAnalysis of the causes of failure, e.g. incorrect muscles injected, inappropriate injection technique, and formation of toxin-neutralising antibodies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraphCxSpLast\" style=\"text-indent: -18.0pt; mso-list: l2 level1 lfo2; mso-hyphenate: auto; tab-stops: 35.45pt; text-autospace: ideograph-numeric ideograph-other;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eRe-evaluation of the relevance of treatment with botulinum toxin A.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"page-break-after: avoid;\"\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003ePaediatric population: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eThe safety and efficacy of Relfydess in children aged \u003cspan style=\"mso-bidi-font-weight: bold;\"\u003eup to 18 years\u003c\/span\u003e have not been established. The use of \u003ca name=\"_Hlk118374513\"\u003e\u003c\/a\u003eRelfydess is not recommended in patients under 18 years. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"page-break-after: avoid;\"\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003eElderly population: \u003c\/span\u003e\u003c\/i\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; mso-ansi-language: EN-US; mso-fareast-language: EN-GB;\"\u003eThere is limited phase 3 clinical data with \u003c\/span\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eRelfydess\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; mso-ansi-language: EN-US; mso-fareast-language: EN-GB;\"\u003e in patients 65 years and older.\u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003e\u003c\/span\u003e\u003c\/i\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eMethod of administration: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eRelfydess should only be administered by health care professionals with appropriate qualifications and expertise in this treatment and having the required equipment, in accordance with national guidelines and legislation. Intramuscular use. \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: SimSun; mso-ansi-language: EN-US; mso-fareast-language: EN-GB;\"\u003eDosing and treatment intervals depend on assessment of the individual patient’s response, but dosing should not exceed maximum doses allowed and the treatment interval should be at least 12 weeks. \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eEach vial should be used for a single patient during a single treatment session only. Any residual product after the treatment should be discarded. Use aseptic technique and standard practice to prevent cross-infections. The median time to onset is 2 to 3 days, with some patients reporting an effect within 1 day. Treatment effect has been demonstrated for 6 months, with up to 75% of patients not returning to baseline. \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';\"\u003eGlabellar lines: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eThe recommended dose for the treatment of glabellar lines in adults is a total of 50 units\/0.5 mL administered by intramuscular injection divided equally (10 units\/0.1 mL per injection) into each of the 5 intramuscular injection sites: 2 injections on each side at the \u003ci style=\"mso-bidi-font-style: normal;\"\u003ecorrugator\u003c\/i\u003e muscle and 1 injection at the \u003ci style=\"mso-bidi-font-style: normal;\"\u003eprocerus\u003c\/i\u003e muscle near the nasofrontal angle. The anatomical landmarks can be more readily identified if palpated and observed at patient maximum frown. Before and during the injection, place the thumb or index finger firmly below the orbital rim in order to prevent extravasation below the orbital rim. The needle bevel should be pointed upward and medially during the injection. In order to reduce the risk of eyelid ptosis, the following steps should be taken:\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman';\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"TableParagraph\" style=\"margin-left: 36.0pt; text-indent: -18.0pt; mso-list: l0 level1 lfo3; mso-hyphenate: auto;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-GB;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB;\"\u003eAvoid injections near the \u003ci\u003elevator palpebrae superioris\u003c\/i\u003e muscle, particularly in patients with larger brow-depressor complexes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraphCxSpFirst\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo3; mso-hyphenate: auto; background: white; mso-background-themecolor: background1; text-autospace: ideograph-numeric ideograph-other;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; color: black; mso-color-alt: windowtext;\"\u003eLateral \u003ci\u003ecorrugator \u003c\/i\u003einjections should be placed at least 1 centimetre above the bony supraorbital ridge.\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraphCxSpMiddle\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo3; mso-hyphenate: auto; background: white; mso-background-themecolor: background1; text-autospace: ideograph-numeric ideograph-other;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; color: black; mso-color-alt: windowtext;\"\u003eEnsure the injected dose (volume) is accurate. \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraphCxSpLast\" style=\"text-indent: -18.0pt; mso-list: l0 level1 lfo3; mso-hyphenate: auto; background: white; mso-background-themecolor: background1; text-autospace: ideograph-numeric ideograph-other;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;\"\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e·\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e       \u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; color: black; mso-color-alt: windowtext;\"\u003eAvoid injecting closer than 1 centimetre above the central eyebrow.\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"TableParagraph\" style=\"text-align: justify; text-justify: inter-ideograph; page-break-after: avoid;\"\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB;\"\u003eLateral canthal lines: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB;\"\u003eThe recommended dose for the treatment of lateral canthal lines in adults is a total of 60 units\/0.6 mL administered by intramuscular injection divided equally into 10 units\/0.1 mL into each of the 6 intramuscular injection sites: 3 injections (30 units\/0.3 mL) on each side at the \u003ci\u003eorbicularis oculi\u003c\/i\u003e muscle. Injections should be given with the needle bevel-up and oriented away from the eye in the lateral \u003ci\u003eorbicularis oculi\u003c\/i\u003e muscle. When lines in the lateral canthal region appear both above and below the lateral \u003ci\u003ecanthus\u003c\/i\u003e, inject above and below lateral canthus. In case lines in the lateral canthal region are mainly below the lateral \u003ci\u003ecanthus\u003c\/i\u003e, inject per below lateral canthus. Lateral canthal line anatomical landmarks can be more readily identified if observed and palpated at maximal smile. Care must be taken to avoid injecting the \u003ci\u003ezygomaticus major\u003c\/i\u003e\/\u003ci\u003eminor\u003c\/i\u003e muscles to avoid lateral mouth drop and asymmetrical smile. \u003ci\u003eGlabellar lines\/lateral canthal lines\u003c\/i\u003e\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB;\"\u003ecombined treatment: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB;\"\u003eFor combination treatment of glabellar lines and lateral canthal lines, the respective individual dosing and administration should be followed for a total dose of 110 units\/1.1 mL of Relfydess. The recommended dose for the treatment of glabellar lines is 50 units\/0.5 mL (10 units\/0.1 mL per injection) into each of 5 intramuscular injection sites and for lateral canthal lines is 60 units\/0.6 mL (10 units\/0.1 mL in each of 6\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB;\"\u003eintramuscular injection sites).\u003ci\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eContraindications: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eKnown hypersensitivity to any botulinum toxin products or to any of the excipients. \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003ePresence of infection at the proposed injection sites. Presence of myasthenia gravis, Eaton Lambert Syndrome or amyotrophic lateral sclerosis. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003ePrecautions and Warnings: \u003c\/span\u003e\u003c\/b\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eGeneral: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eRelfydess should not be injected into a blood vessel. As with all intramuscular injections, use of Relfydess is not recommended in patients who have a prolonged bleeding time. Patients treated with the recommended dose may experience exaggerated muscle weakness. Each vial of Relfydess must be used for a single patient treatment during a single session. Any excess of unused product must be disposed of and specific precautions must be taken for the inactivation and disposal of any unused solution. \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eHypersensitivity reactions: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eSerious and\/or immediate hypersensitivity reactions have been reported for botulinum toxin products and anaphylactic reactions can occur very rarely (see \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e‘Undesirable Effects’\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003e). These reactions include anaphylaxis, serum sickness, urticaria, soft tissue oedema, and dyspnoea. Equipment and medications (including adrenaline) needed to treat anaphylaxis should therefore be readily available\u003ci\u003e. \u003c\/i\u003eIf such a reaction occurs, further injection of Relfydess should be discontinued, and appropriate medical therapy immediately instituted. \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eSpread of Toxin effect:\u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"mso-bidi-font-size: 11.0pt;\"\u003e \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003ePost-marketing safety data from other approved botulinum toxin products suggest that botulinum toxin effects (such as diplopia, blurred vision and ptosis) may be observed beyond the site of local injection (see section 4.8). \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; font-family: 'Times New Roman',serif;\"\u003eIn addition, adverse reactions possibly related to the spread of toxin effect distant from the site of injection have been reported very rarely with botulinum toxin and may include asthenia, generalised muscle weakness, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eThese symptoms are consistent with the mechanism of action of botulinum toxins and have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. More specifically, following treatment with botulinum toxin, very rare cases of death have been reported in the context of patients who have dysphagia, pneumopathy, or significant asthenia. Therefore, Relfydess is not recommended in such patients. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech or respiratory disorders arise\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e. \u003ci\u003ePre-existing neuromuscular disorders: \u003c\/i\u003eRelfydess should be used with caution in patients with a risk of, or clinical evidence of, marked defective neuro-muscular transmission. These patients may have an increased sensitivity to agents such as botulinum toxin, and excessive muscle weakness (including systemic effects of severe dysphagia and respiratory compromise) may follow treatment. In some of these cases, dysphagia has lasted several months and required placement of a gastric feeding tube. \u003ci\u003ePre-existing conditions at the injection site: \u003c\/i\u003e\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eCaution should be taken when Relfydess is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the targeted muscle(s). Caution should be used when Relfydess treatment is used in patients who have marked facial asymmetry, ptosis, excessive skin laxity (such as dermatochalasis), deep dermal scarring, or thick sebaceous skin. \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eOphthalmic adverse reactions\u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003e: \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eDry eye, reduced tear production, reduced blinking, and corneal disorders may occur with the use of botulinum toxins. If symptoms of dry eye (e.g., eye irritation, photophobia, or visual changes) persist, consider referring the patient to an ophthalmologist. Increased lacrimation may occur with the use of botulinum toxins.\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eMuscle atrophy: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eMuscle atrophy is expected after repeated botulinum treatment secondary to the flaccid paralysis of the treated muscles. \u003ci\u003eAntibody formation: \u003c\/i\u003eInjections at more frequent intervals or at higher doses may increase the risk of neutralising antibody formation to botulinum toxin. Clinically, the formation of neutralising antibodies may reduce the effectiveness of subsequent treatment. \u003ci\u003eTraceability: \u003c\/i\u003eIn order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. \u003ci\u003ePotassium and Sodium content: \u003c\/i\u003eThis medicine contains potassium, less than 1 mmol (39 mg) per 150 units vial, i.e. essentially ‘potassium-free’. This medicine contains less than 1 mmol sodium (23 mg) per 150 units vial, i.e. essentially ‘sodium-free’. \u003ci\u003ePolysorbate 80 content\u003c\/i\u003e\u003c\/span\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 15.0pt;\"\u003e: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eThis medicine contains 1.6 mg of polysorbate 80 per 150 units vial which is equivalent to 1.1 mg\/mL. Polysorbates may cause allergic reactions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"page-break-after: avoid;\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eInteractions: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eNo drug interaction studies have been conducted. Concomitant treatment with Relfydess and aminoglycosides or other agents interfering with neuromuscular transmission (e.g. curare-like agents or other botulinum toxin products in other locations) should only be used with caution since the effect of botulinum toxin may be potentiated. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003ePregnancy, Breastfeeding and Fertility: \u003c\/span\u003e\u003c\/b\u003e\u003ci\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003ePregnancy: \u003c\/span\u003e\u003c\/i\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eThere are no adequate data from the use of botulinum toxin type A in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity other than at high doses causing maternal toxicity. The potential risk for humans is unknown. Relfydess should not be used during pregnancy and in women of childbearing potential not using contraception. \u003ci\u003eBreastfeeding: \u003c\/i\u003eIt is unknown if Relfydess is excreted in human milk. The excretion of Relfydess in milk has not been studied in animals.\u003cspan style=\"mso-spacerun: yes;\"\u003e  \u003c\/span\u003eRelfydess should not be used during breast-feeding. \u003ci\u003eFertility\u003c\/i\u003e: There are no clinical data examining the effect of Relfydess on fertility.\u003cspan style=\"mso-spacerun: yes;\"\u003e  \u003c\/span\u003eThere is no evidence of direct effect of botulinum toxin A on fertility in animal studies. \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eEffects on ability to drive and use machines: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eOther botulinum toxin products have been reported to have a minor or moderate influence on the ability to drive and\/or use machines. There is a potential risk of localised muscle weakness or visual disturbances linked with the use of Relfydess which may temporarily impair the ability to drive or operate machinery.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"mso-layout-grid-align: none; text-autospace: none;\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; color: black;\"\u003eUndesirable\u003c\/span\u003e\u003c\/b\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e Effects: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003eThe majority of adverse reactions reported after one treatment with Relfydess in \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; font-family: 'Times New Roman',serif;\"\u003esubjects receiving ≥ 50 units in all placebo-controlled studies in the development program\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003e were of mild to moderate intensity. The most frequently reported adverse reactions were injection site reactions and headache occurring in approximately 7% and 5% of subjects, respectively. In general, treatment\/injection technique-related reactions occurred within the first month following injection and were transient.\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; font-family: 'Times New Roman',serif;\"\u003e When glabellar lines and lateral canthal lines were treated in combination, the nature and frequency of adverse reactions were comparable to what was observed when patients were treated for the individual indications. \u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eThe following adverse reactions were observed in patients that were administered Relfydess for the temporary improvement in the appearance of moderate to severe glabellar lines: Common (≥ 1\/100 to \u0026lt; 1\/10): Headache, eyelid ptosis, injection site reactions (e.g. bruising, swelling, pruritus, pain, discomfort,\u003cspan style=\"mso-spacerun: yes;\"\u003e  \u003c\/span\u003ehaematoma, hypersensitivity and warmth), uncommon (≥ 1\/1,000 to \u0026lt;1\/100): Hypersensitivity, visual impairment, dry eye, asthenopia, brow ptosis, urticaria, muscular weakness, muscle spasm. The following adverse reactions were observed in patients that were administered Relfydess for the temporary improvement in the appearance of moderate to severe lateral canthal lines: Common (≥ 1\/100 to \u0026lt; 1\/10): Headache, injection site reactions (e.g. erythema, pain, and bruising), uncommon (≥ 1\/1,000 to \u0026lt;1\/100): Hypersensitivity, dry eye, asthenopia, swelling of eyelid, muscular weakness.\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; mso-bidi-font-size: 9.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"page-break-after: avoid; text-autospace: none;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoPlainText\"\u003e\u003cu\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003ePrescribers should consult the summary of product characteristics for further details.\u003c\/span\u003e\u003c\/u\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eMA Number: \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003ePA1613\/005\/001\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eLegal Category:\u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003cspan style=\"mso-spacerun: yes;\"\u003e  \u003c\/span\u003e\u003cspan style=\"mso-bidi-font-weight: bold;\"\u003ePOM\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eFurther information is available from:\u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003cspan style=\"mso-bidi-font-weight: bold;\"\u003eGalderma (U.K.) Limited, Evergreen House North, Grafton Place, London, NW1 2DX, United Kingdom, Tel: \u003c\/span\u003e\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;\"\u003e+44 (0)300 3035674.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eDate of Revision\u003c\/span\u003e\u003c\/b\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e:\u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e January 2026\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eIE-REL-2600001\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv style=\"mso-element: para-border-div; border: solid black 1.0pt; mso-border-alt: solid black .5pt; padding: 1.0pt 4.0pt 1.0pt 4.0pt;\"\u003e\n\u003cp class=\"MsoNormal\" align=\"center\" style=\"text-align: center; border: none; mso-border-alt: solid black .5pt; padding: 0cm; mso-padding-alt: 1.0pt 4.0pt 1.0pt 4.0pt;\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/b\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 11.0pt; line-height: 115%;\"\u003e▼ \u003c\/span\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 11.0pt; line-height: 115%;\"\u003eThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See below for how to report adverse reactions:\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp class=\"MsoNormal\" align=\"center\" style=\"text-align: center; border: none; mso-border-alt: solid black .5pt; padding: 0cm; mso-padding-alt: 1.0pt 4.0pt 1.0pt 4.0pt;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003eSuspected adverse events can be reported via HPRA Pharmacovigilance, Website: \u003c\/span\u003e\u003ca href=\"http:\/\/www.hpra.ie\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003ewww.hpra.ie\u003c\/span\u003e\u003c\/a\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-bidi-font-weight: bold;\"\u003e;\u003c\/span\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e\u003cspan style=\"mso-spacerun: yes;\"\u003e  \u003c\/span\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" align=\"center\" style=\"text-align: center; border: none; mso-border-alt: solid black .5pt; padding: 0cm; mso-padding-alt: 1.0pt 4.0pt 1.0pt 4.0pt;\"\u003e\u003cb style=\"mso-bidi-font-weight: normal;\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eAdverse events should also be reported to Galderma (U.K.) Limited and Healthxchange Ireland Limited.\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"color: rgb(0, 0, 0);\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003eE-mail: \u003c\/span\u003e\u003ca href=\"mailto:medinfo.uk@galderma.com\" style=\"color: rgb(0, 0, 0);\"\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: Verdana;\"\u003emedinfo.uk@galderma.com\u003c\/span\u003e\u003c\/a\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e Tel: \u003c\/span\u003e\u003cspan lang=\"EN\" style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-ansi-language: EN;\"\u003e+44 \u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;\"\u003e(0)300 3035674\u003c\/span\u003e\u003cspan style=\"font-size: 10.0pt; font-family: 'Times New Roman',serif;\"\u003e \u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp style=\"text-align: center;\"\u003e\u003cspan style=\"color: rgb(0, 0, 0);\"\u003e\u003cspan style=\"font-size: 10.5pt; mso-bidi-font-size: 11.0pt; line-height: 115%;\"\u003eE-mail: \u003cspan style=\"text-decoration: underline;\"\u003eorders@healthxchange.ie\u003c\/span\u003e Tel: 01 456 8360\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":54724706435340,"sku":"GALRELF100","price":90.99,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALRELF100.jpg?v=1773836574"},{"product_id":"reladose-6-pack-syringe","title":"Reladose 6-pack syringe","description":"\u003cp\u003eTo be used with \u003ca href=\"https:\/\/shop.healthxchange.ie\/products\/relfydess-100-units\"\u003eRelfydess\u003c\/a\u003e. \u003c\/p\u003e","brand":"Galderma","offers":[{"title":"Default Title","offer_id":54736917889292,"sku":"GALRELFSYR6","price":0.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/files\/GALRELFSYR6.jpg?v=1775653149"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/7317\/0444\/collections\/GaldermaLogo.jpg?v=1762342099","url":"https:\/\/shop.healthxchange.ie\/collections\/galderma.oembed","provider":"Healthxchange Ireland Limited","version":"1.0","type":"link"}